Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN4 | Q9Y3Q4 | 7/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.34 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846082 | 0.95 | HCN4 (0.51) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL12332636 | 0.94 | HCN4 (0.55) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL15858419 | 0.92 | HCN4 (0.64) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL333491 | 0.92 | HCN4 (0.64) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL31280 | 0.92 | HCN4 (0.64) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL30284992 | 0.92 | HCN4 (0.64) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Hydrochloric Acid SCHEMBL14696912 | 0.91 | HCN4 (0.63) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Oxalic Acid SCHEMBL2594327 | 0.90 | HCN4 (0.59) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Oxalic Acid SCHEMBL2594323 | 0.90 | HCN4 (0.59) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| SCHEMBL16203194 | 0.89 | HCN4 (0.60) | HCN4CHRM2HTR1ASLC6A4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927708-B2 | Process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one compounds, and application in the synthesis of ivabradine | LES LABORATOIRES SERVIER (FR) | 2015-01-06 | — | — | US | disclosed |
| US-20140296512-A1 | PROCESS FOR THE SYNTHESIS OF 7,8-DIMETHOXY-1,3-DIHYDRO-2H-3-BENZAZEPIN-2-ONE COMPOUNDS, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE | LES LABORATOIRES SERVIER (FR) | 2014-10-02 | — | — | US | disclosed |
| EP-2487158-B1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | SERVIER LAB (FR) | 2013-02-20 | — | — | EP | disclosed |
| EP-2202225-B1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | SERVIER LAB (FR) | 2012-10-24 | — | — | EP | disclosed |
| US-8278440-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-10-02 | — | — | US | disclosed |
| EP-2364972-B1 | New method for synthesising ivabradine and its addition salts | SERVIER LAB (FR) | 2012-09-19 | — | — | EP | disclosed |
| US-20120208996-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2012-08-16 | — | — | US | disclosed |
| EP-2487158-A1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | Les Laboratoires Servier (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-20120172589-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2012-07-05 | — | — | US | disclosed |
| US-8212026-B2 | Process for the preparation of ivabradine hydrochloride and polymorph thereof | IND-SWIFT LABORATORIES LIMITED (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2241554-A1 | Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts | Les Laboratoires Servier (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010112704-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE AND THE ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010112705-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE AND THE ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249398-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249397-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-09-30 | — | — | US | disclosed |
| WO-2010072930-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE | LES LABORATOIRES SERVIER (FR) | 2010-07-01 | — | — | WO | disclosed |
| EP-2202225-A1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | Les Laboratoires Servier (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-06-24 | — | — | US | disclosed |
| EP-1589005-B1 | Process for the synthesis of Ivabradine and its pharmaceutically acceptable acid addition salts | SERVIER LAB (FR) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005110993-A1 | NOVEL METHOD OF SYNTHESISING IVABRADINE AND THE SALTS THEREOF FOR ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208996-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | HCN4 37/4885CHRM2 2611/4885HTR1A 1678/4885 |
| US-20140296512-A1 | PROCESS FOR THE SYNTHESIS OF 7,8-DIMETHOXY-1,3-DIHYDRO-2H-3-BENZAZEPIN-2-ONE COMPOUNDS, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE | KCNB1, KCNB2, KCNMB1 | HCN4 95/4885CHRM2 2135/4885HTR1A 491/4885 |
| US-20100249398-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | HCN4 37/4885CHRM2 2611/4885HTR1A 1678/4885 |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | HCN4 37/4885CHRM2 2611/4885HTR1A 1678/4885 |
| US-20120172589-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | HCN4 37/4885CHRM2 2611/4885HTR1A 1678/4885 |
| US-20100249397-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | HCN4 37/4885CHRM2 2611/4885HTR1A 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.